Rigel(US:RIGL)2022-05-03 21:03TAVALISSE in ITP - Q1 2022 net product sales reached $16.2 million[20] - Bottles shipped to patients and clinics increased by 15% compared to Q1 2021[20] - Customer interactions increased, with approximately 65% being in-person interactions[21] wAIHA Opportunity - The company estimates a potential market opportunity of over $1 billion in the US for wAIHA[12] - Enrollment is complete for the Phase 3 FORWARD study, with topline data expected in mid-2022[11] - In a Phase 2 clinical trial, 46% of patients with wAIHA responded to fostamatinib, and 29% achieved a durable response[42] COVID-19 Program - A Rigel-led Phase 3 clinical trial for fostamatinib in hospitalized COVID-19 patients has enrolled 268 patients as of May 2, 2022[12] - Positive results from an NIH/NHLBI-sponsored Phase 2 trial were published in Clinical Infectious Disease[12] Pipeline Programs - A Phase 1b study of R289, an IRAK1/4 inhibitor, is underway in lower-risk MDS[12] - Rigel and Lilly are planning to initiate a Phase 2 study of R552, a RIPK1 inhibitor, in an immunologic disease in Q1 2023[84] Financial Position - Cash, cash equivalents, and short-term investments totaled $107.5 million as of March 31, 2022[95]